Dialogue Volume 14 Issue 2 2018 | Page 39

We are seeing devastating consequences for individuals, families and communities as a result of the opioid crisis Dr. Jeff Sisler, Executive Director, Profes- sional Development and Practice Support with the College of Family Physicians of Canada. “We are pleased to support the Opioid Wisely recommendations that encourage more discussion between patients and their health-care providers to explore other options for pain management.” Dr. Laurent Marcoux, President of the Canadian Medical Association, says the more information patients and prescribers have, the better the outcome will be. “As providers of care, we want to have a key role in ensuring the evidence-based use of these medications to keep Canadians safe,” he said. Twelve organizations have already released opioid-related recommendations, as of the Opioid Wisely launch on March 1. These include the College of Family Physicians of Canada, the Canadian Society of Internal Medi- cine, and the Society of Obstetricians and Gynaecologists of Canada. Below we publish the recommenda- tions from the College of Family Physicians of Canada. To learn more about the Opioid Wisely campaign, and to view the complete set of recommendations and patient materials, visit ChoosingWiselyCanada.org/opioid- wisely. Additional recommendations will be released in the near future. Family Medicine Recommendations (the College of Family Physicians of Canada) Don’t continue opioid analgesia beyond the immedi- ate postoperative period or other episode of acute, severe pain. The immediate postoperative period or acute episodes of pain typically refers to a time period of three days or less, and rarely more than seven days. Prescribe the lowest effective dose and number of doses required to address the expected pain. This recommendation does not apply to individu- als already on long-term or chronic opioids or opi- oid agonist treatment. Don’t initiate opioids long-term for chronic pain until there has been a trial of available non-phar- macological treatments and adequate trials of non- opioid medications. Depending on the pain mechanism and patient co-mor- bidities, this can include acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs)